Millennium Management’s Blueprint Medicines BPMC Stock Holding History

Millennium Management’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-25,000	Closed	-$2.18M	–	5883
2024 Q4	$2.18M	Buy	+25,000	New	+$2.29M	﹤0.01%	3570
2024 Q2	–	Sell	-10,400	Closed	-$987K	–	5916
2024 Q1	$987K	Buy	+10,400	New	+$892K	﹤0.01%	4304
2022 Q3	–	Sell	-40,000	Closed	-$2.02M	–	7070
2022 Q2	$2.02M	Buy	+40,000	New	+$2.34M	﹤0.01%	3698
2021 Q1	–	Sell	-55,000	Closed	-$6.17M	–	5934
2020 Q4	$6.17M	Buy	+55,000	New	+$5.8M	﹤0.01%	2240
2020 Q3	–	Sell	-150,000	Closed	-$11.7M	–	4462
2020 Q2	$11.7M	Buy	+150,000	New	+$10.1M	0.02%	1111
2020 Q1	–	Sell	-125,100	Closed	-$10M	–	3880
2019 Q4	$10M	Sell	125,100 -24,900	-17%	-$1.86M	0.01%	1377
2019 Q3	$11M	Buy	150,000 +75,000	+100%	+$6.48M	0.02%	1210
2019 Q2	$7.08M	Hold	75,000	–	–	0.01%	1512
2019 Q1	$6M	Buy	+75,000	New	+$5.54M	0.01%	1624

Other funds holding BPMC

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Millennium Management's BPMC Position: Q3 2025 in Review

Millennium Management sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 295,879 shares — an estimated $37.9M sold.

Millennium Management first reported a position in BPMC in Q2 2015 and held it in 32 quarters. The position peaked at $67.6M in Q2 2024. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

Millennium Management reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
Millennium Management sold 295,879 Blueprint Medicines shares in Q3 2025, an estimated $37.9M.
Millennium Management first reported a position in Blueprint Medicines in Q2 2015 and held it in 32 quarters.
Millennium Management's Blueprint Medicines position peaked at $67.6M in Q2 2024.
5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on Millennium Management's 13F filing for Q3 2025, filed 14 Nov 2025.